Vancomycin in Primary Sclerosing Cholangitis in Italy

PHASE2RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

June 15, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Primary Sclerosing CholangitisLiver and Intrahepatic Bile Duct DisorderIBD
Interventions
DRUG

Oral Vancomycin

The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.

OTHER

Placebo

The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.

Trial Locations (1)

20900

RECRUITING

Fondazione IRCCS San Gerardo dei Tintori, Monza

All Listed Sponsors
collaborator

Genetic s.p.a.

UNKNOWN

lead

University of Milano Bicocca

OTHER